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Abstract The mechanism underlying type I angiotensin I1 (Ang 
II) receptor (ATI receptor) desensitisation is unknown. Struc- 
tural features uggest it may be a substrate for protein kinase C 
(PKC). The effects of a selective PKC inhibitor, Ro 31-7549, on 
receptor desensitisation were investigated in CHO cells express- 
ing the human ATI receptor. Desensitisation was demonstrated 
with respect o the calcium response to Ang II in Fura-2 -loaded 
cells. Ro 31-7549 had no effect on desensitisation. However, 
pretreatment with Ro 31-7549 caused a dose-dependent reduction 
in calcium release from intracellular stores. PKC may therefore 
act at a locus distal from the receptor itself. 
Key wm'ds. Angiotensin receptor: Desensitisation; Protein 
kinase C: Calcium release: Fura 2; CHO cell 
I. Introduction 
Angiotensin I1 tAng II) plays a crucial role in controlling 
blood pressure through its potent vasoconstrictor effect, and in 
mineral homeostasis by effects on adrenal aldosterone synthesis 
[1]. These effects are mediated by the AT1 subtype of the Ang 
II receptor (AT1 receptor) via coupling to a guanine nucleotide 
regulatory protein (G protein) [2] and leading to activation of 
phospholipase (7 (PLC) - beta. This, in turn, results in the 
hydrolysis of phosphatidyl inositol, with the consequent pro- 
duction of the second messengers inositol (1,4,51 trisphosphate 
(lnsP3) and sn-1,2-diacylglycerol (DAG) [3]. lnsP3 acts through 
the InsP3 receptor to release calcium from intracellular lnsP~- 
sensitive calcium stores [4-5] while DAG acts within the plane 
of the membrane to activate protein kinase C (PKC). A process 
of calcium entry into the cell also occurs through calcium chan- 
nels located on the plasma membrane [6]. In addition, following 
initial stimulation by Ang 1I, the ATI receptor undergoes a
process of desensitisation [7]. The mechanism underlying this 
process has yet to be defined for this receptor. 
Four putative sites for phosphorylation by protein kinase C 
(PKC) have been identified in the carboxy terminal of the 
human ATI ihAT1) receptor [8]. This suggests that PKC has 
a direct effect on the receptor itself and thus may be important 
in ATI receptor-mediated signal transduction or, by analogy 
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to the effect of cAMP-dependent protein kinase (PKA) in the 
fl-adrenergic receptor system [9], in receptor desensitisation. 
However, a specific role for PKC in AT I receptor function is 
yet to be established. Activation of PKC inhibits Ang 11 de- 
pendent PLC activation in vascular smooth muscle cells [10], 
while studies in isolated perfused rat kidney, using the non- 
selective PKC inhibitor staurosporine, have suggested that 
PKC potentiates Ang ll-induced vasoconstriction [11]. In con- 
trast, in bovine adrenal glomerulosa cells inhibition of PKC 
partially attenuates Ang II induction of c-los mRNA [12] and 
aldosterone secretion in bovine [I 3] and rat [14] adrenal glom- 
erulosa cells, respectively. In terms of Ang II receptor descnsi- 
tisation, use of the non-selective PKC inhibitor, staurosporinc. 
or activation of PKC using phorbol ester has yielded different 
results in different systems. Shimuta et al. [15], have demon- 
strated that Ang ll-induced desensitisation i  guinea pig ileum 
and cultured guinea pig myocytes is inhibited by staurosporine 
and enhanced by phorbol ester. A similar effect of stauro- 
sporine has been shown for Ang 11 receptors coupled to chlo- 
ride channels in Xenopus oocytes [16]. However, desensitisation 
was shown to be independent of PKC in neonatal cardiomy- 
ocytes [17]. 
In this paper we report studies on chinese hamster owlry 
(CHO) cells stably transfected with the human AT1 receptor 
gene (CHO.hATI cells), in which we have investigated the role 
of PKC in ,\TI receptor function using the selective PKC 
inhibitor, Ro 31 7549 [18 22]. 
2. Materials and Methods 
2.1. Fura-2 studies 
CHO cells were routinely cultured in Hanfs F12 medium containing 
10% v/v FBS Icomplete medium). Alter harvesting cells using trypsin- 
EDTA (0.5% w/v trypsin; 0.02% w/v EDTA), cells were allowed to 
re-equilibrate in complete medium, in the presence or absence of the 
various inhibitors and activators of PKC described below, for 3(I min 
prior to washing twice into 5 mM HEPES buffer containing 140 mM 
NaC1, 4 mM KC1, 1 mM MgCI:, 1 mM NaHePO4. 11 mM i>glucose 
and 0. I% bovine serum albumin (BSA) (w/v1, pH 7.4. Cells were loaded 
in fresh HEPES buffer (containing BSA) at 37°C f\~r 30 min with 4,aM 
Fura-2/AM (Calbiochem-Novabiochem, tlK~, and washed twice in 
HEPES butler without BSA and resuspended in a final volume of 2 ml. 
For calcium replete conditions, extracellular calcium was increased to 
hnM with CaCL. Measurements of intracellular calcium were con- 
ducted in an RF-5000 dual wavelength fluorescence spectrophotometer 
(Shimadzu) at wavelengths of 340 nm and 38(1 nm, at a temperature of
25°C. The cell suspensions were calibrated for leakage using manganese 
chloride (200 ,aM final concentration) followed by diethylenetriamine- 
pentaacetic acid solution treated with calcium carbonate (CaDTPA) 
(400 ,aM). Eslimates for Fura-2 fluorescence at infinite and zero cal- 
cium concentrations were obtained using 1(10/JM digitonin and 50 mM 
EGTA (final concentrations), respectively. Values fl)r intracellular cal- 
cium were calculated by the formula used in [23], assuming a dissocia- 
tion constant of Fura-2 for calcium at 25°(7 of 150 nM [241. 
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2.2. Ligand binding assays 
Cells were prepared as above but, instead of loading with Fura-2/ 
AM, cells were aliquoted into eppendorf tubes at a density of approx- 
imately 10 6 cells/tube (in 50 pl HEPES buffer containing 0.1% BSA). 
50 pl of buffer (uncompeted tubes) or buffer containing unlabelled Ang 
II (final concentration i  150 pl final volume ranging from 0.1 nM 
100 nM) was added, followed by 50/11 [125I]lSar, SIle-Ang II (2000 
Ci/mmol; Amersham; final concentration 0.15 nM). After incubation 
for I h at 22°C, tubes were transferred toan ice-bath and 850/A ice-cold 
assay buffer was added. The suspension was then centrifuged at 
6000 x g for 20 s at 4°C. Supernatants were aspirated and a further 
aliquot of ice-cold buffer added. After a second wash, cells were pelleted 
at 12,000 x g and counted by gamma counter. Values for receptor 
capacity and affinity were obtained by Scatchard analysis. 
3. Results 
3.1. Homologous desensitisation of A T1 receptor 
The CHO'hAT1 cells expressed high affinity binding for 
Ang II which was displaceable by Dup 753 (data not shown). 
To examine receptor desensitisation in these cells we deter- 
mined the effect of serial exposure to Ang II on calcium mobil- 
isation. A sub-maximal dose of Ang II (20 nM) induced arapid 
and transient peak of calcium mobilisation (179 + 21 nM above 
basal; n = 6) followed by a sustained mobilisation of calcium 
(Fig. 1). No change in basal calcium was observed for 
CHO • NEO cells (stably transfected with only the neomycin 
resistance gene) (data not shown). 100 nM Ang II was found 
to produce a maximal stimulation under these conditions 
(270 + 20 nM calcium peak increase above basal; n = 3). Fol- 
lowing initial exposure to 20 nM Ang II, the sustained plateau 
phase of calcium mobilisation was allowed to proceed for peri- 
ods of up to 20 min after which a second maximal dose of Ang 
II (100 nM) was added. As can be seen in Fig. 1 no further 
peaks of calcium mobilisation were observed in response to 
Ang II. However, subsequent addition of 0.1% FBS triggered 
a calcium response, indicating that the calcium stores were not 
depleted and suggesting that serum-initiated calcium release is 
not similarly desensitised. 
3.2. Effects of Ro 31-7549 
Pre-treatment of CHO.hAT1 cells with 15/IM Ro 31-7549 
had no effect on AT1 receptor desensitisation (data not shown). 
Pre-treatment (30 min) with either the non-selective PKC inhib- 
itor, staurosporine (100 nM), or PKC activators, phorbol 12- 
myristate 13-acetate (PMA; 1 yM) and 1-oleoyl-2-acetyl-sn- 
glycerol (OAG; 10 yM), was also without effect (data not 
shown). However, pre-treatment with Ro 31 7549 produced a
small, but significant, reduction in the height of the calcium 
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Fig. 1. Calcium mobilisation i  CHO cells expressing the human AT1 
receptor in response to sub-maximal Ang II (20 nM), showing clear 
desensitisation t wards ubsequent maximal Ang II (100 nM) stimula- 
tion. 
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Fig. 2. Representative traces howing change in intracellular calcium 
in reponse to Ang II (20 nM) in (a) CHO' hAT1 cells pretreated with 
DMSO vehicle; (b) CHO. hATI cells pretreated with Ro 31 7549 (15 
/IM); and (c) CHO" NEO cells. 
peak, reducing the percentage increase in peak calcium 
over basal by 27 + 8% (n = 3) relative to cells treated with 
DMSO vehicle alone (Fig. 2). Pre-treatment with the CaM 
kinase inhibitor KN-62 (Research Biochemicals International) 
(100 nM) had no such effect (data not shown). After removal 
of extracellular calcium using EGTA (2 mM final concentra- 
tion), the effect of 15 ,uM Ro 31-7549 was much more pro- 
nounced, reducing the calcium peak by 66 + 5% (n -- 4) com- 
pared to DMSO treated control cells (Fig. 3). This inhibitory 
effect was dose dependent and was also observed in 
CHO • hAT1 cells pre-treated with staurosporine (Fig. 3). De- 
spite almost complete inhibition of calcium release from intra- 
cellular stores, high doses of Ro 31-7549 (22.5/IM) had no 
affect on receptor desensitisation (data not shown). 
Furthermore, pre-treatment with Ro 31-7549 (22.5 pM) had no 
significant effect on either AT1 receptor concentration r affin- 
ity in these cells (Table 1). 
4. Discussion 
Previous work by other groups has made use of the trans- 
fected CHO cell system to study rat ATla receptor function 
[25-28]. However, this is the first report of functional analysis 
of the human AT1 receptor in this system. The hAT1 receptor 
showed profound homologous desensitisation (Fig. 1), a phe- 
nomenon which was unaffected by modulation of PKC by 
inhibitors (Ro 31-7549 and staurosporine), or activators (PMA 
and OAG), or the CaM kinase inhibitor, KN-62. This suggests 
that PKC has no effect on hATI receptor desensitisation in this 
system. This lack of effect has also been shown in neonatal 
cardiomyocytes [17] but contrasts with the effects of PKC on 
Ang II receptor desensitisation in guinea pig tissue [15] and on 
the Xenopus angiotensin receptor (xAT) [16]. The differences 
between these observations may be the result of species differ- 
ences, either in Ang II receptor structure, or in the nature of 
target cell specific signal transduction and desensitisation 
mechanisms. It is possible that receptor internalisation may 
play a part in ATI receptor desensitisation. It has been shown 
that AT1 receptor internalisation ccurs in bovine [29] and rat 
[30] adrenal glomerulosa cells and that rat ATIa receptors 
expressed in CHO cells also undergo internalisation [28]. It is 
notable, however, that in neonatal cardiomyocytes [17], where 
PKC had no effect on desensitisation, there was also no loss of 
surface receptor capacity associated with desensitisation. 
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Fig. 3. Dose-dependent reduction in calcium peak after pretreatment 
with Ro 31 7549 under calcium deplete conditions. *P<0.05 
** P < 0.01 ; *** P < 0.001, (compared to DMSO control) Student's t-test. 
1NSET: Representative trace showing effect of 15 ,uM Ro 31 7549 (a), 
compared with DMSO-treated (control) cells (b), under calcium-de- 
plete conditions. 
Despite the apparent lack of PKC effect on desensitisation 
it is clear that PKC can affect Ang II induced calcium mobili- 
sation in CHO.hATI  cells. Inhibit ion of PKC by Ro 31 7549 
resulted in a substantial decrease in calcium release from intra- 
cellular stores (Fig. 3). This suggests that PKC in some way 
facilitates Ang II-stimulated calcium release. However, this 
does not appear to be at the level of the ATI receptor itself, 
since Ro 31 7549 had no effect on binding of labelled Ang lI 
(Table 1). Inhibit ion of PKC activation of PLC-beta, and thus 
a reduction in lnsP3 formation, could explain the results seen 
in Fig. 3, however, PKC phosphorylat ion of PLC-beta has been 
shown to be inhibitory to this moiety [32]. One possible point 
at which PKC may act could be at the level of the InsP3 
receptor. As PKC has been shown to phosphorylate the InsP3 
receptor [3 I], it is tempting to propose a role for PKC in sensi- 
tising the latter. 
In our study, the inhibit ion of PKC by Ro 31 7549 appeared 
to induce calcium influx to an extent which virtually masked 
the attenuation i  calcium release identified under calcium de- 
plete conditions (Fig. 2b). This was greater than the influx 
normally expected concomitant ly with calcium release from 
intracellular stores. It has been shown that, at doses above 
10rim Ang I I, calcium influx during the initial transient calcium 
peak is attenuated, or that the rate of influx is no greater than 
the basal rate [33,34]. However, a study of rat AT1 receptor 
expressed in CHO cells suggested there was a contr ibut ion from 
calcium influx during the initial transient peak [25]. Recent data 
has indicated that Ang It- induced activation of PKC is depend- 
ent on calcium entry [35]. It is possible, therefore, that inhibi- 
Table 1 
Angiotensin It binding characteristics in CHO.hATI cells 
K<~ (nM) Bm~ × (fmol/mg protein) 
Control (DMSO) 0.74 _+ 0.07 389 -+ 35 
Ro 31-7549 (22.5 uM) 0.84 + 0.09 369 -+ 41 
Values represent mean + S.D. from three determinations. 
tion of PKC prevents some feedback suppression of calcium 
entry by direct interaction of PKC with a calcium channel. 
In conclusion, we have demonstrated a lack of effect of PKC 
on desensitisation of the human ATI receptor expressed in 
CHO cells. However, inhibit ion of PKC by Ro 31 7549 reduces 
release of calcium from intracellular stores and leads to an 
apparent compensatory influx of calcium. One could speculate 
that sensitisation of the InsP3 receptor may be a novel role for 
PKC in Ang II stimulated signal transduction and that PKC 
may also be important  in control l ing calcium channel opening. 
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